Clinical trials: Sepsis Bacterial
Oropharyngeal Candidiasis, Candidemia
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
- Conditions
- Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
- Trial name
- NCT00608335
- Testing
- Micafungin
- Where
- 13 sites in United States, South Africa
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Urinary Tract Infections, Meningitis
Febrile Infant Diagnostic Assessment and Outcome Study
Febrile infants under 3 months of age represent a high risk group for invasive bacterial infection (IBI) and UTI with approximately 10-20% having bacteremia, meningitis or urinary tract infection.
- Conditions
- Urinary Tract Infections, Meningitis, Sepsis, Bacterial Infections
- Trial name
- FIDO (NCT05259683)
- Where
- United Kingdom
- Volunteers
- 2,076 people
- Sponsor
- Queen's University, Belfast
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neonatal SEPSIS, Very Low Birth Weight Baby
Efficacy of IgM Rich Immunoglobulin With Antibiotics for Bacterial Sepsis in Very Low Birth Weight Preterm Neonates
Study comprises of giving IVIG to half of the septic VLBW preterm neonates along with ongoing antibiotics and placebo to the other half. The immunoglobulin will be given for 3 days and neonates will be monitored for the results.
- Trial name
- IgMNS (NCT03403530)
- Testing
- IgM rich Immunoglobin
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sir Takhtasinhji General Hospital
Staphylococcus Aureus Bacteremia
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT00622882
- Testing
- infectious disease specialist consultation
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Sepsis, Neonatal Mortality
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
The CLEAN (ChLorine to reduce Enteric and Antibiotic resistant infections in Neonates) cluster randomized controlled trial in western Kenya will evaluate the impact of a multi-component chlorination intervention in health care…
- Conditions
- Sepsis, Neonatal Mortality, Antibiotic Resistant Infection, Enteric Infections
- Trial name
- CLEAN (NCT06824350)
- Testing
- chlorination for water disinfection and surface disinfection, infection prevention and control messaging
- Where
- 2 sites in United States, Kenya
- Volunteers
- 45,450 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Bacteremia, Bacteremia Sepsis
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
This project will evaluate the usefulness of Monocyte Distribution Width (MDW) for the diagnosis of blood culture positivity (BSI) in patients in the Emergency Department (ED) and reevaluate the usefulness of MDW in patients with…
- Conditions
- Bacteremia, Bacteremia Sepsis, Sepsis, Septic Shock
- Trial name
- NCT05296590
- Testing
- Monocyte Distribution Width (MDW) , observation
- Where
- United States
- Volunteers
- 50,000 people
- Sponsor
- Henry Ford Health System
Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset
Serosurveillance Study of Maternally Derived Anti-GBS Antibody
Globally, neonatal mortality remains unacceptably high, with little change in the death rate in the first 28 days of life since 1990, despite reductions in under-5 mortality of up to 50% over the same period.
- Conditions
- Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset, Group B Streptococcus Neonatal Sepsis
- Trial name
- ProGreSs (NCT04549220)
- Where
- Uganda
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset
Serocorrelate of Protection Against GBS (PREPARE WP3)
A multicentre, international case-control study to develop a biobank of sera from 150 cases of serotype III GBS disease and associated clinical information from seven countries (Malawi, Uganda, UK, the Netherlands, Italy and…
- Conditions
- Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset, Group B Streptococcus Neonatal Sepsis
- Trial name
- NCT04732026
- Where
- 6 sites in France, Italy and 4 more
- Volunteers
- 600 people
- Sponsor
- St George's, University of London
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
Having bacteria in the blood can be very dangerous. This is called bacteraemia (or bacteremia) or bloodstream infection. It can lead to problems across the whole body, which is what happens in sepsis.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Sepsis Bacterial, Bloodstream Infection
- Trial name
- PET-SAB (NCT05361135)
- Testing
- PET/CT
- Volunteers
- 820 people
- Sponsor
- University College, London
Sepsis, Sepsis Bacterial
A Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor
The overall purpose of this study is to demonstrate the usability of a clinical-grade device in the form of a finger clasp similar to a pulse oximeter for monitoring lactate values, by comparing its performance in reading…
- Conditions
- Sepsis, Sepsis Bacterial, Lactate Blood Increase, Infectious Disease
- Trial name
- NCT04796285
- Testing
- Lab Clasp
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Bacteremia, Endocarditis
Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections
Before Daptomycin (Cubicin ®) approved by the U.S. FDA in 2003, There were large-scale clinical trials conducted that included more than 1,000 subjects and than Daptomycin got complicated skin and soft tissue infections (CSSSI)…
- Conditions
- Bacteremia, Endocarditis, Serious Gram-positive Infections
- Trial name
- NCT01301638
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Far Eastern Memorial Hospital
Sepsis, Septic Shock
Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2.
- Conditions
- Sepsis, Septic Shock, Sepsis, Severe, Infections
- Trial name
- BIOSEP (NCT06178822)
- Testing
- No intervention
- Where
- 3 sites in Netherlands
- Volunteers
- 3,300 people
- Sponsor
- Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Bloodstream Infection
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P.
- Trial name
- SHORTEN2 (NCT05210439)
- Testing
- Short-treatment of any active antibiotic regimen, Long-treatment of any active antibiotic regimen
- Where
- 37 sites in Spain
- Volunteers
- 306 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Sepsis
Evaluation of Usage Patterns and Outcomes in Patients Receiving Ceftolozane/Tazobactan (C/T) in Brazilian Hospitals
Ceftolozane/Tazobactan (C/T) is a recent option to manage multidrug resistant gram-negative infections in hospital patients. Despite several randomized controlled trials describing safety and efficacy of C/T, real world evidence…
- Trial name
- NCT05267483
- Testing
- No intervention
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- D'Or Institute for Research and Education
Sepsis, Septic
Evaluation of the Clinical Relationship Between Procalcitonin Level and Bacteremia Agent in Intensive Care Unit Patients
In intensive care units, sepsis, which can be defined as bacteremia and the irregular and uncontrolled inflammatory response to it, is one of the most important causes of mortality.
- Conditions
- Sepsis, Septic, Bacteremia and Sepsis, Intensive Care Medicine
- Trial name
- NCT06958354
- Where
- Turkey (Türkiye)
- Volunteers
- 1,529 people
- Sponsor
- Gulhane Training and Research Hospital
Infection in ICU, Sepsis
Early Optimization of Ceftazidime Regimen in Critical Care
Hospital-acquired infections, most of which are caused by Gram-negative bacteria, are common in intensive care units and have a major impact on patient prognosis.
- Conditions
- Infection in ICU, Sepsis, Septic Shock, Pseudomonas Aeruginosa Infection
- Trial name
- FORTOPTIM_1 (NCT07085624)
- Testing
- ceftazidime, plasma ceftazidime dosage
- Where
- 8 sites in France
- Volunteers
- 128 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Acute Myeloid Leukemia
Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy
Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of sepsis scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia…
- Trial name
- LAM-SEPSIS (NCT05249894)
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Urinary Tract Infection Complicated, Acute Pyelonephritis
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02168946
- Testing
- Vabomere, Best Available Therapy
- Where
- 50 sites in United States, Argentina and 6 more
- Volunteers
- 77 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Fungemia
Prospective Population Study on Candidemia in Spain
The aim of this study is to describe the epidemiology of fungal blood infections in Spain (with emphasis on the incidence, fungal species distribution and antifungal susceptibility).
- Trial name
- CANDIPOP (NCT01236261)
- Testing
- Non intervention
- Where
- 29 sites in Spain
- Volunteers
- 730 people
- Sponsor
- Fundacion SEIMC-GESIDA